Generics Bulletin Podcasts

エピソード

• 
  Off-Patent, On Record: Navigating The Financial Strategy Behind Litigation With Sandoz’s Julia Pike 06.10.2026 24分

  In the third episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė is joined by Sandoz’s head of IP Julia Pike to analyze the European intellectual property system, how it compares to the US, and the financial decisions behind litigation for off-patent companies. For any podcast feedback or queries, you can now reach us at [email protected].
• 
  The Generics Bulletin Podcast: Discussing Sandoz’s Strategy Updates As It Prepares For A Biosimilars Boom 09.09.2026 13分

  On September 8, Sandoz revealed a slew of strategy updates and forecasts at a capital markets day at the London Stock Exchange. Generics Bulletin editor Dave Wallace was there, and discusses the key details with deputy editor Dean Rudge.
• 
  Off-Patent, On Record: A Story Of Patients Fighting For Accessible Cystic Fibrosis Treatment 02.09.2026 22分

  In the second episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė hears how patients with cystic fibrosis travelled to Bangladesh to collect generic version of Vertex’s highly inaccessible Trikafta. Urtė is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner.
• 
  Generic Bulletin Trailer 19.08.2026 1分
• 
  Off-Patent, On Record: View Through The Journalist's Lens With Generics Bulletin's Dave Wallace 04.08.2026 24分

  Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor for 16 years.
• 
  The Next Era Of Oncology Biosimilars 22.07.2026 17分

  Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries. In this podcast, ICON experts Colin Farquharson and Martin Lachs, discuss how scientific innovation, evolving standards of care and changing market dynamics are influencing the next generation of oncology biosimilars. This podcast explores: How oncology biosimilars are moving from proof of concept towards broader adoption The potential opportunities and challenges associated with antibody-drug conjugates and bispecific antibodies Why patent expiry alone is not enough to determine the long-term viability of an asset The factors influencing physician confidence, patient acceptance and market uptake How real-world evidence can strengthen confidence in biosimilar safety and efficacy The analytical, CMC, regulatory and market-planning capabilities sponsors should develop early
• 
  The Generics Bulletin Podcast: Summer Conferences 20.07.2026 22分

  Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira.
• 
  The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin 18.06.2026 28分

  The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin Description: Generics Bulletin senior reporter Urtė Fultinavičiūtė talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.
• 
  The Generics Bulletin Podcast: Biosimilars Conference Report And Big M&A Deals 14.05.2026 27分

  Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, attended by deputy editor Dean Rudge; while editor Dave Wallace talks about the latest big deals in biosimilars and what is behind them.